Table 2. Baseline demographic and clinical parameters.

	n	%	Median survival [months]	95%-CI	p-value
Age					0.163
<64 Years	199	49.1	15.5	12.2–18.8
>64 Years	206	50.9	23.1	18.1–29.7
Sex					0.3872
Female	70	17.3	19.6	14.4–32.7
Male	335	82.7	17.2	14.4–21.7
ECOG					<0.0001*
0	219	60.7	22.9	16.9–28.8	0 vs. 1: 0.002*
1	115	31.9	13.7	9.8–20.3	1 vs. 2: 0.061
2	21	5.8	3.9	2.1–23.1	2 vs. 3: 0.108
3	6	1.7	1.6	0.5–8.4
Liver cirrhosis					0.0417*
No	66	16.3	28.4	18.9–38.2
Yes	338	83.7	16.1	14.1–21.3
Ascites					<0.0001*
No	266	66.5	25.6	21.1–29.7	No vs. mo:<0.0001*
Moderate	89	22.3	11,.1	7.3–15.2	Mo. vs. ma: <0.0001*
Massive	45	11.3	3.3	2.3–4.5
Hepatic Encephalopathy					0.1605
No	291	77.4	20.1	15.6–24.1
Yes	85	22.6	11.7	7.6–21.4
Portal Hypertension					0.0310*
No	141	36.3	25.6	15.5–30.8
Yes	247	63.7	16.1	14.1–20.6
Portal vein thrombosis					<0.0001*
No	327	81.6	21.4	17.2–25.6	No vs. part: <0.0001*
Partial	54	13.5	6.0	3.9–15.2	Part. vs. comp: 0.182
Complete	20	5.0	4.4	1.9–9.2

(* = statistically significant). Mo = moderate, ma = massive, part = partial, comp = complete.